Bessemer Group Inc Ligand Pharmaceuticals Inc Transaction History

Bessemer Group Inc

$61.3 Billion
Q4 2024

A detailed history of Bessemer Group Inc transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Bessemer Group Inc holds 38 shares of LGND stock, worth $4,560. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Holding current value

$4,560

% of portfolio

0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$99.95 - $129.9 $3,798 - $4,936	38 New	38 $4,000
Q2 2023 Aug 10, 2023	BUY	$69.53 - $79.33 $1,182 - $1,348	17 New	17 $1,000
Q3 2020 Nov 12, 2020	SELL	$89.56 - $126.72 $1,164 - $1,647	-13 Closed	0 $0
Q1 2020 Apr 30, 2020	SELL	$63.37 - $107.88 $126 - $215	-2 Reduced 13.33%	13 $1,000
Q4 2019 Feb 04, 2020	BUY	$96.94 - $113.59 $96 - $113	1 Added 7.14%	15 $1,000
Q3 2019 Nov 07, 2019	BUY	$86.25 - $120.16 $1,207 - $1,682	14 New	14 $1,000
Q2 2019 Jul 19, 2019	SELL	$107.38 - $129.34 $1,610 - $1,940	-15 Closed	0 $0
Q1 2019 May 13, 2019	SELL	$105.93 - $142.47 $694,371 - $933,890	-6,555 Reduced 99.77%	15 $2,000
Q4 2018 Feb 12, 2019	BUY	$128.36 - $272.13 $50,188 - $106,402	391 Added 6.33%	6,570 $891,000
Q3 2018 Nov 06, 2018	BUY	$211.18 - $274.49 $37,801 - $49,133	179 Added 2.98%	6,179 $1.7 Million
Q1 2018 May 10, 2018	SELL	$138.63 - $182.62 $27,726 - $36,524	-200 Reduced 3.23%	6,000 $991,000
Q4 2017 Jan 30, 2018	BUY	$128.36 - $147.04 $331,040 - $379,216	2,579 Added 71.22%	6,200 $849,000
Q3 2017 Nov 03, 2017	BUY	$120.91 - $137.94 $437,815 - $499,480	3,621	3,621 $493,000

Others Institutions Holding LGND

# of Institutions

275

Shares Held

18.5M

Call Options Held

28.8K

Put Options Held

View Full List

About LIGAND PHARMACEUTICALS INC

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $2.03B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

More about LGND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bessemer Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Bessemer Group Inc with notifications on news.

Account